Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 4/20 | 0.40 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.40 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.36 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.36 |
| ▸ | PTGES | O14684 | 2/20 | 0.35 |
| ▸ | FYN | P06241 | 1/20 | 0.34 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.34 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.34 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.34 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.34 |
| ▸ | SLC5A2 | P31639 | 1/20 | 0.33 |
| ▸ | RET | P07949 | 1/20 | 0.33 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.33 |
| ▸ | AR | P10275 | 1/20 | 0.33 |
| ▸ | CNR2 | P34972 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7572092 | 0.79 | CYP19A1 (0.56) | CYP19A1CYP11B1CYP11B2 | |
| SCHEMBL7575872 | 0.76 | CYP19A1 (0.46) | CYP19A1LRRK2CYP11B1CYP11B2PDE3A | |
| SCHEMBL20105141 | 0.75 | HDAC1 (0.41) | CYP19A1LRRK2 | |
| SCHEMBL7137268 | 0.73 | CYP19A1 (0.50) | CYP19A1CYP11B1CYP11B2 | |
| SCHEMBL7575275 | 0.73 | PELI1 (0.40) | LRRK2ADORA1CYP2A6 | |
| SCHEMBL7570638 | 0.72 | CYP19A1 (0.49) | CYP19A1AR | |
| SCHEMBL10629429 | 0.72 | ESR2 (0.52) | LRRK2ADORA1CYP2A6CNR2 | |
| SCHEMBL7576136 | 0.72 | AR (0.47) | CYP19A1LRRK2CYP11B1CYP11B2ADORA1 | |
| SCHEMBL7569910 | 0.72 | CYP19A1 (0.43) | CYP19A1CYP11B1CYP11B2 | |
| SCHEMBL7569343 | 0.71 | MAPT (0.50) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020019527-A1 | Substituted phenyl farnesyltransferase inhibitors | ABBOTT LABORATORIES | 2002-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020019527-A1 | Substituted phenyl farnesyltransferase inhibitors | FNTA, FNTB, SLC10A1 | CYP19A1 589/4885LRRK2 3748/4885CYP11B1 94/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.